

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Localized Delivery of CRISPR/dCas9 via Layer-by-Layer Self-Assembling**

2 **Peptide Coating on Nanofibers for Neural Tissue Engineering**

3  
4 Kunyu Zhang <sup>a, 1</sup>, Wai Hon Chooi <sup>a, 1</sup>, Shuang Liu <sup>b</sup>, Jiah Shin Chin <sup>a, c</sup>, Aoife Murray <sup>d</sup>, Dean  
5 Nizetic <sup>d, e</sup>, Du Cheng <sup>b</sup>, Sing Yian Chew <sup>a, d, \*</sup>

6  
7 <sup>a</sup> School of Chemical & Biomedical Engineering, Nanyang Technological University, 637459  
8 Singapore

9 <sup>b</sup> Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education,  
10 School of Materials Science and Engineering, Sun Yat-Sen University, Guangzhou 510275,  
11 China

12 <sup>c</sup> NTU Institute of Health Technologies, Interdisciplinary Graduate School, Nanyang  
13 Technological University, Singapore 639798, Singapore

14 <sup>d</sup> Lee Kong Chian School of Medicine, Nanyang Technological University, 308232 Singapore

15 <sup>e</sup> The Blizzard Institute, Barts & The London School of Medicine, Queen Mary University of  
16 London, 4 Newark St., London E1 2AT, United Kingdom

17  
18 <sup>1</sup> These authors contributed equally to this work.

19  
20 \* Corresponding author: [sychew@ntu.edu.sg](mailto:sychew@ntu.edu.sg) (S. Y. Chew)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Keywords:** genome editing, gene delivery, CRISPR/Cas9, electrospinning, nerve regeneration

**Abstract:** The clustered regularly interspaced short palindromic repeat (CRISPR) systems have a wide variety of applications besides precise genome editing. In particular, the CRISPR/dCas9 system can be used to control specific gene expression by CRISPR activation (CRISPRa) or interference (CRISPRi). However, the safety concerns associated with viral vectors and the possible off-target issues of systemic administration remain huge concerns to be safe delivery methods for CRISPR/Cas9 systems. In this study, a layer-by-layer (LbL) self-assembling peptide (SAP) coating on nanofibers is developed to mediate localized delivery of CRISPR/dCas9 systems. Specifically, an amphiphilic negatively charged SAP<sup>-</sup> is first coated onto PCL nanofibers through strong hydrophobic interactions, and the pDNA complexes and positively charged SAP<sup>+</sup>-RGD are then absorbed via electrostatic interactions. The SAP-coated scaffolds facilitate efficient loading and sustained release of the pDNA complexes, while enhancing cell adhesion and proliferation. As a proof of concept, the scaffolds are used to activate GDNF expression in mammalian cells, and the secreted GDNF subsequently promotes neurite outgrowth of rat neurons. These promising results suggest that the LbL self-assembling peptide coated nanofibers can be a new route to establish a bioactive interface, which provides a simple and efficient platform for the delivery of CRISPR/dCas9 systems for regenerative medicine.

1  
2  
3  
4 **1. Introduction**  
5  
6  
7

8       The clustered regularly interspaced short palindromic repeat (CRISPR) systems have  
9  
10 evolved as powerful tools for precise genome editing in diverse biological applications [1, 2].  
11  
12 These systems use a single guide RNA (sgRNA) to direct the Cas9 nuclease to the target gene,  
13  
14 resulting in gene deletion, insertion, and mutation [1-4]. Additionally, a transcriptional regulator  
15  
16 can be fused to the dead Cas9 (dCas9), in which the two catalytic domains of Cas9 are  
17  
18 inactivated and thus have no cleavage activity [5]. This allows the CRISPR/dCas9 system to be  
19  
20 used to activate or interfere with specific gene expression, named CRISPR activation (CRISPRa)  
21  
22 and CRISPR interference (CRISPRi) respectively [6, 7]. Unfortunately, apart from these  
23  
24 promising features, challenges remained for the CRISPR/Cas9 system to be translated for  
25  
26 clinical applications. Although viral vectors like adeno-associated virus (AAV) have shown great  
27  
28 efficacy in CRISPR/Cas9 system delivery, the immunogenic response and long-term expression  
29  
30 of viral vectors are still the main concerns [8, 9]. Meanwhile, the uptake of the vectors by  
31  
32 undesired tissue or organ, especially during systemic administration, may cause off-target issues,  
33  
34 which may lead to tumorigenic or other deleterious events. To overcome these limitations, we  
35  
36 sought to develop an effective non-viral approach to deliver CRISPR/Cas9 components in a  
37  
38 sustained and localized fashion, which is often required for tissue regeneration.  
39  
40  
41  
42  
43  
44  
45  
46

47       Polycaprolactone (PCL) is widely used for the fabrication of tissue engineering scaffolds by  
48  
49 various techniques, including electrospinning and 3D printing [10, 11], owing to its  
50  
51 machinability, structural stability, biocompatibility and biodegradability. However, the intrinsic  
52  
53 hydrophobicity and absence of reactive ligands on PCL lead to ineffective cell adhesion and  
54  
55 biomolecules immobilization, which hinders the further development of the scaffolds for tissue  
56  
57 engineering. In addition, the chemical and biological stability of PCL makes it difficult for  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 surface modification. Lately, inspired by mussel adhesion chemistry, many groups, including  
2 ourselves, have demonstrated the easy-to-operate polydopamine coating strategy on PCL  
3 scaffolds, which could significantly enhance cell-substrate interactions and biomolecule  
4 immobilizations [12-19]. Such bioadhesive coating allowed effective scaffold-mediated delivery  
5 of Cas9-sgRNA ribonucleoprotein to cells [18]. However, although the mechanism is still  
6 unclear, the special surface chemistry of polydopamine has been reported to be not favorable to  
7 some sensitive cells [18]. Therefore, we aim to develop a novel coating strategy that is more  
8 cytocompatible and allows scaffold surface-mediated delivery of CRISPR/dCas9 system for  
9 CRISPRa. We delivered the systems through dCas9 plasmid DNA (pDNA) in this study due to  
10 its low cost, flexibility, and stability, which is useful for us to test on the new coating platform  
11 [20]. As a proof of concept, scaffold-mediated gene activation of Glial cell derived neurotrophic  
12 factor (GDNF) would be an interesting strategy to stimulate nerve regeneration as it delivers both  
13 topographical and biochemical cues to guide cellular and tissue regrowth.

14 In this study, we successfully fashioned a layer-by-layer (LbL) self-assembling peptide  
15 (SAP) coating on nanofibers that can mediate localized delivery of CRISPR/dCas9 system to  
16 promote neural regeneration. We first established an easy-to-operate approach for the bioactive  
17 functionalization of PCL nanofibers by SAP. These SAP-coated nanofibers exhibited good  
18 affinity towards pDNA/PEIpro complexes and hence could facilitate the efficient loading and  
19 sustained release of such complexes. Owing to the incorporation of RGD peptides, the scaffolds  
20 could also support cell adhesion and proliferation. Other than the RGD, our SAP-based scaffold  
21 design also allows facile incorporation of other bioactive peptides, thereby offering a superb  
22 platform for the investigation of cell-substrate interactions. Furthermore, due to these promising  
23 features, the scaffolds were capable of localized delivery of CRISPR/dCas9 system to activate

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 GDNF expression in mammalian cells, and the secreted GDNF could subsequently promote  
2 neurite outgrowth. We believe that the strategy reported in this work opens up a new route to  
3 establish a bioactive interface and a simple and efficient platform for the delivery of  
4 CRISPR/dCas9 systems for regenerative medicine.

## 6 **2. Materials and methods**

### 7 *2.1. Materials*

8 Polycaprolactone (average Mw = 80000), 2,2,2-trifluoroethanol (TFE), heparin sodium salt and  
9 Triton-X 100 were purchased from Sigma-Aldrich (USA). Sodium hydroxide was purchased  
10 from Merck (Germany). All chemicals were used as received without further purification. The  
11 self-assembling peptide, SAP<sup>-</sup> (FEFEFEFE) and SAP<sup>+</sup>-RGD (FKFKFKFKGGRGDSP), were  
12 synthesized by Genscript (USA) and characterized by HPLC and ESI-MS (Supplementary  
13 Methods Section 1. Characterization of SAP). Paraformaldehyde (PFA, 4%) was purchased from  
14 Santa Cruz Biotechnology. PEIpro transfection reagent was purchased from Polyplus (USA).  
15 Plasmid pSpCas9(BB)-2A-GFP (PX458) (“Cas9-GFP”; 9288 bp) was a gift from Feng Zhang  
16 (Addgene plasmid #48138) (Fig. S3) [21], and SP-dCas9-VPR (“dCas9-VPR”; 11,319 bp) was a  
17 gift from George Church (Addgene plasmid #63798) (Fig. S4) [22]. sgRNA expression vector  
18 (3028 bp) harboring a U6 promoter positioned upstream of the customized sgRNA sequence was  
19 obtained from Genscript (USA) and confirmed by DNA sequencing. The sequences of sgRNA  
20 are shown in Table S1. Fibroblast growth factor-2 was purchased from Peptidech (USA). M-  
21 MLV Reverse Transcriptase was obtained from Promega (USA). Human GDNF Duoset ELISA  
22 kit was purchased from R&D system (USA). Label IT nucleic acid labeling kit was obtained

1  
2  
3  
4 1 from MirusBio (USA). SingleShot SYBR Green One-Step Kit and iTaq Universal SYBR Green  
5  
6 2 One-Step Kit were purchased from Bio-Rad (USA). hMSCs were purchased from Lonza  
7  
8  
9 3 (Switzerland). All other cell culture reagents, Quant-iT PicoGreen dsDNA assay kit, Click-iT  
10  
11 4 EdU cell proliferation assay kit and SYBR Select Master Mix were purchased from  
12  
13  
14 5 ThermoFisher (USA).  
15  
16  
17  
18 6  
19  
20

## 21 7 *2.2. Fabrication of LbL SAP-coated nanofibers*

22  
23  
24 8 Electrospun nanofibers were fabricated according to our previous report [18]. In brief, small  
25  
26 9 strips of PCL films with thickness of 20  $\mu\text{m}$  were adhered onto coverslips ( $\text{\O}$  18 mm) to create a  
27  
28  
29 10 1  $\text{cm}^2$  area, and the coverslips were then placed on a rotation wheel (2400 rpm) for the collection  
30  
31  
32 11 of electrospun nanofibers. The PCL solution (14 wt% in TFE) was loaded into a syringe and  
33  
34 12 dispensed at a fixed rate (1.0  $\text{mL h}^{-1}$ ) by a syringe pump. Voltages of +8 kV and -4 kV were  
35  
36 13 then applied to the blunt needle tip and the rotating collector, respectively. The distance between  
37  
38  
39 14 spinneret and collector was set as 22 cm. The obtained electrospun fibers were sterilized by UV  
40  
41  
42 15 irradiation for 30 min followed by incubation in 70% ethanol for 10 min.  
43  
44

45 16  $\text{SAP}^-$  and  $\text{SAP}^+$ -RGD peptide powders were dissolved in sterilized 0.1 mM NaOH solution (1%,  
46  
47 17 w/v) and 0.1 mM HCl (1%, w/v), respectively, and sonicated for 30 min prior to use. To get the  
48  
49  
50 18 LbL assembled scaffolds, 50  $\mu\text{L}$  of  $\text{SAP}^-$  solution (0.2%, w/v) was firstly dripped onto the PCL  
51  
52 19 nanofibers to cover the 1  $\text{cm}^2$  scaffold area. After incubation at 37  $^\circ\text{C}$  for 2 h, the scaffolds were  
53  
54  
55 20 rinsed with DI  $\text{H}_2\text{O}$  to remove uncombined peptides. 4  $\mu\text{L}$  of PEIpro (1 mg/mL) were diluted in  
56  
57  
58 21 DI  $\text{H}_2\text{O}$  before complexation with 4  $\mu\text{g}$  of plasmids (N/P = 8). The complexation was performed  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 at room temperature for 15 min and then placed onto the scaffolds to allow adsorption at 37 °C  
2 for 1 h. The unbonded complexes were removed by washing with DI H<sub>2</sub>O, and 50 μL of SAP<sup>+</sup>-  
3 RGD solution (0.2%, w/v) was then added onto the scaffolds. After incubation at 37 °C for 2 h,  
4 the scaffolds were rinsed again with DI H<sub>2</sub>O to remove uncombined peptides. To investigate the  
5 sequential alternation of surface charges during LbL coating, the PCL nanoparticles (Ø ~ 400 nm)  
6 were coated with the same protocol and the zeta-potential was measured by Malvern Nano-ZS  
7 Zeta Sizer after each step. The experiment was repeated 3 times.

### 8 9 *2.3. SEM characterization of scaffolds*

10 The lyophilized samples were sputter-coated with platinum at 10 mA for 100 s, and then the  
11 surface morphology of the scaffolds was observed under a scanning electron microscope (SEM,  
12 JOEL, JSM-6390LA) at a 10-kV accelerating voltage. The average fiber diameters were  
13 measured by ImageJ (NIH) with at least 100 fibers per sample.

### 14 15 *2.4. Water contact angle measurements*

16 To study the surface wettability of SAP-coated PCL scaffolds, the static water contact angles of  
17 PCL, PCL@SAP<sup>-</sup> and PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds were measured by the sessile drop  
18 method using a contact angle analyzer (Kruss DSA 25). The droplet volume was set as 2 μL.  
19 Measurements were carried out at least 3 times for each scaffold.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1    2.5. *FT-IR measurements*

2    To evaluate changes in chemical bond characteristics of the PCL scaffolds before and after SAP  
3    coating, FTIR was carried out by using a Fourier-transform infrared spectrometer (PerkinElmer  
4    Spectrum One). Spectra were acquired in the 400 – 4000 cm<sup>-1</sup>. The samples were subjected to  
5    flash freezing and lyophilization prior to the measurement.

7    2.6. *Characterizations of complex loading and release*

8    To visualize the distribution of pDNA/PEIpro complexes on the scaffolds, pDNA was tagged  
9    with MFP488 using Label IT nucleic acid labeling kit as per the manufacturer’s instructions. The  
10   MFP488-tagged pDNA was then complexed with PEIpro and adsorbed onto the scaffolds  
11   according to the protocol mentioned above. The scaffolds were then visualized under an  
12   epifluorescence microscope (Leica DMI8).

13    To test the loading efficiency of the pDNA/PEIpro complexes on the scaffolds, the rinsate  
14   during coating processes was collected carefully. After de-complexion from the pDNA/PEIpro  
15   complexes using heparin sodium salt (1:1 v/v, 20 µg mL<sup>-1</sup>), the amount of pDNA in the rinsate  
16   was determined using the Quant-iT PicoGreen dsDNA assay kit according to manufacturer’s  
17   protocol. The experimental loading efficiencies were computed using the following equation:

$$\text{Loading efficiency (\%)} = \frac{m_t - m_u - m_l}{m_t} \times 100\%$$



1 where  $m_t$  is the total mass of pDNA used for loading,  $m_u$  is the mass of unbound pDNA (pDNA  
2 remained in the complex coating solution) and  $m_l$  the mass of pDNA loss during the coating of  
3  $SAP^+$ -RGD (pDNA released into the  $SAP^+$ -RGD coating solution).

4 Subsequently, the scaffolds were incubated with 1 mL of PBS at 37 °C. While culture media  
5 better mimics the cell culture condition, the other components in the culture media or serum  
6 protein may affect the DNA assay reactions and plate reader readings. At each time point, 1 mL  
7 of PBS was collected from each sample and replaced with an equal volume of fresh PBS. The  
8 supernatant was then used to measure the amount of pDNA by the same protocol mentioned  
9 above.

## 11 *2.7. Cell culture*

12 U2OS cells were a generous gift from Professor Wenting Zhao at Nanyang Technological  
13 University. The U2OS cells and hMSCs were cultured in high-glucose DMEM with GlutaMAX,  
14 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The medium change  
15 was performed every 2-3 days. hNPCs were generated from induced-pluripotent stem cells as  
16 described previously [23]. The cells were cultured on poly-L-ornithine and laminin-coated  
17 culture dishes in maintenance medium, which consisted of DMEM/F12 supplemented with 1%  
18 glutaMAX, 1% N2 supplement, 2% B27 supplement, 1% penicillin/streptomycin and 20 ng mL<sup>-1</sup>  
19 FGF2. All the cells were cultured in a humidified incubator at 37 °C and 5% CO<sub>2</sub>. Passage 6  
20 hMSCs and passage 9 hNPCs were used in this study.

1  
2  
3  
4 1 *2.8. Cell adhesion, proliferation and scaffold-mediated local transfection*

5  
6  
7  
8 2 To assess the effects of different surface coatings on cell adhesion, U2OS and hMSCs were  
9  
10 3 seeded at a density of 10,000 cells cm<sup>-2</sup>, while hNPCs were seeded at a density of 50,000 cells  
11  
12 4 cm<sup>-2</sup>. To assess the effects of the SAP-coating on cell proliferation, the cell-seeded scaffolds  
13  
14  
15 5 were incubated with 10 mM EdU for 24 h before being fixed with 4% PFA. The scaffolds were  
16  
17 6 permeabilized with 0.25% Triton-X then stained with the Click-iT reaction cocktail and Hoechst  
18  
19  
20 7 33342. In each group, over 10 images from at least 3 scaffolds were taken at 20×, and at least  
21  
22 8 200 cells were quantified. The number of nuclei and EdU labelled nuclei were counted. For  
23  
24  
25 9 scaffold-mediated local transfection experiments, the Cas9-GFP plasmid was used, in which the  
26  
27 10 2A-GFP was fused to Cas9 to allow the detection of Cas9 expression in the transfected cells, and  
28  
29  
30 11 the U2OS cells were also seeded at a density of 10,000 cells cm<sup>-2</sup>. After incubation at 37 °C for  
31  
32 12 48 h, the cells were fixed with 4% PFA solution for 10 min and then permeabilized in 0.25%  
33  
34  
35 13 Triton-X 100 in PBS for 15 min at room temperature. For morphology studies, the cytoskeleton  
36  
37 14 was stained with Alexa Fluor 555 phalloidin or Alexa Fluor 488 phalloidin, and nuclei were  
38  
39  
40 15 stained with DAPI. Fluorescent images were acquired with an epifluorescence microscope (Leica  
41  
42 16 DMI8) and analyzed using Image J (NIH). In each group, over 10 images from at least 3  
43  
44 17 scaffolds were taken using a 20× objective, and at least 50 cells were quantified. The circularity  
45  
46  
47 18 of cells was computed using the following equation:

48  
49  
50 19 
$$C = 4\pi AP^{-2}$$

51  
52  
53  
54 20 where A is the area occupied by cell and P is the perimeter of cell. Higher circularity means less  
55  
56 21 spreading. In addition, the total cell number was counted by DAPI, while the GFP<sup>+</sup> cells were  
57  
58  
59 22 counted based on the co-localization of GFP and DAPI signals.

## 2.9. Subcutaneous implantation

To assess the biocompatibility of the SAP-coated scaffolds *in vivo*, 1 × 1 cm PCL fiber scaffolds with thickness of  $94 \pm 4.7 \mu\text{m}$  were prepared with or without SAP coating according to the procedure mentioned. All experimental procedures that involved animals were performed in accordance with the Nanyang Technological University's Institutional Animal Care and Use Committee, (IACUC, NTU) guidelines. Sprague-Dawley rats (8 weeks, 200-250g) were anesthetized with isoflurane before shaving their backs. Thereafter, subcutaneous pockets were created using surgical scissors after 1.2 cm incisions were made beside the spinal column. Following that, the scaffolds were inserted into the subcutaneous pockets such that each animal received both plain and SAP-coated scaffolds. The wounds were then closed with suture and the animals were observed for 5 days. After 5 days, animals were sacrificed and the tissues enclosing scaffolds were harvested and fixed in 4% PFA overnight. Thereafter, the scaffolds were dehydrated, embedded in paraffin and sectioned to obtain 5  $\mu\text{m}$  thick sections. The sections were then stained with Haematoxylin and Eosin (H&E) and imaged with ZEISS Axio Scan.Z1 using a 20× objective. The images were then analyzed by an experimenter blinded to experimental groups. Semi-quantitative evaluation was performed on the scaffold biocompatibility based on fibrotic tissue formation, presence of macrophages (rounded morphology) at the boundary of the scaffold, and fibroblasts (elongated morphology) infiltration into the scaffold; using a scoring system, +: minimal, ++: some, +++: moderate, ++++: significant (n = 4 rats). To further evaluate inflammatory response towards the scaffolds, the number of macrophages and neutrophils in the scaffolds were counted. A total of 18 evenly distributed ROIs (50  $\mu\text{m}$  × 50  $\mu\text{m}$ ) were assessed for each sample (n = 4 rats).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1

2 *2.10. Bolus transfection experiments*

3 A preliminary test has been performed with different transfection reagents, including  
4 Lipofectamine 3k, L-PEI, PEIpro, and JetOPTIMUS (Fig. S14). PEIpro demonstrated one of the  
5 highest transfection efficiency and acceptable toxicity and hence was used for the subsequent  
6 experiments. For gene activation experiments, U2OS cells were seeded onto 24-well plates at a  
7 density of 20,000 cells per well. Twenty-four hours after plating, cells were transfected with  
8 Cas9-GFP plasmids or a 1:1 mass ratio of dCas9 plasmid:sgRNA plasmids. A total plasmid mass  
9 of 0.5 µg per well was transfected using 0.5 µL per well of PEIpro reagent. For synergy  
10 experiments, the amount of total sgRNA was kept constant and the mass ratio of each sgRNA  
11 was 1:1 or 1:1:1. The cells were harvested 2 d after transfection, and gene expression analysis  
12 was performed.

13

14 *2.11. Scaffold-mediated gene activation in mammalian cells*

15 For exogenous gene-activation experiments, the dCas9 expression plasmids and sgRNA  
16 plasmids were co-delivered with a mass ratio of 1:1, and the sub-mass ratio of each sgRNAs was  
17 1:1:1. U2OS cells were seeded onto the scaffolds at a density of 10,000 cells cm<sup>-2</sup> in 200 µL  
18 culture medium. The medium was sufficient to cover the 1 cm<sup>2</sup> scaffold area. Three experiments  
19 were performed. Gene activation was verified by gene expression analysis (Section 2.12). The  
20 amount of GDNF secreted by the U2OS cells on the scaffolds was quantified by ELISA.  
21 Specifically, the 200 µl medium was collected every 24 h and replaced with 200 µL fresh

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 medium for 3 days, and the collected medium was then stored at -80 °C for subsequent assays  
2 (Section 2.13). To test the bioactivity of the secreted GDNF, medium was collected after 3 days  
3 of culture without medium replacement. Thereafter, the collected medium was added to the  
4 cortical neurons and DRG explant cultures as conditioned medium (Section 2.14).

6 *2.12. Gene expression analysis*

7 After 2 days of culture, cells seeded on the 24-well plates were lysed by TRIzol reagent, and  
8 RNA was extracted according to the manufacturer’s instructions. The RNA concentration was  
9 determined by the NsD-1000 spectrophotometer (NanoDrop Technologies), and 500 ng of RNA  
10 from each sample were reverse transcribed into cDNA using M-MLV Reverse Transcriptase.  
11 Real-time PCR was performed on the StepOnePlus system (Applied Biosystems) using SYBR  
12 Select Master Mix. The sequences of the primers are listed in Table S2 and GAPDH was used as  
13 the housekeeping gene. The primers were checked to have similar amplification efficiency. The  
14 PCR parameter was 10 min at 95 °C, followed by 15 s at 95 °C and 1 min at 60 °C for 40 cycles.  
15 The relative gene expression was calculated using the  $\Delta\Delta C_T$  method, where the fold difference  
16 was calculated using the expression  $2^{-\Delta\Delta C_T}$ . For cells that were seeded on the scaffolds, the cells  
17 were lysed by SingleShot SYBR Green One-Step Kit and PCR was performed with iTaq  
18 Universal SYBR Green One-Step Kit according to the manufacturer’s instructions.

20 *2.13. ELISA assay*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 The amount of secreted GDNF in the medium was quantified using the media obtained in  
2 Section 2.11. Specifically, after the scaffolds were functionalized with SAP coatings and  
3 plasmids, U2OS cells were seeded onto the scaffolds at a density of 10,000 cells cm<sup>-2</sup> in 200 µl  
4 medium. The medium was collected every 24 h and replaced with 200 µl fresh medium for three  
5 days. The collected medium was stored in -80 °C freezer until quantification and was measured  
6 by using a human GDNF ELISA kit following the manufacturer' s instructions without dilution.  
7 In brief, 96-well microplate was coated with 100 µL/well of the Capture Antibody and incubated  
8 overnight at room temperature, followed by washing with wash buffer for three times. Thereafter,  
9 non-specific binding was blocked with Reagent Diluent at room temperature for 1 h prior to  
10 wash for three times. The samples and standards were then added into the coated wells (100 µL  
11 each) and incubated for 2 h at room temperature. The antigen was then incubated with 100 µL of  
12 Detection Antibody for 2 h, followed by the solution of Streptavidin-HRP A for 20 min in dark.  
13 The addition of Substrate Solution (100 µL each) started the color reaction which was stopped 20  
14 min later with 50 µL of Stop Solution. The optical density of each well was immediately  
15 measured at 450 nm with a reference wavelength at 570 nm. GDNF concentrations were  
16 determined from the regression line for the GDNF standard ranging from 31.3 to 500 pg/mL.  
17 Each sample represents one scaffold. Medium from three control and CRISPRa-GDNF scaffolds  
18 was measured.

19  
20 *2.14. Cortical neurons and DRG explants culture*

21 To test for the bioactivity of the GDNF secreted by the U2OS cells on the functionalized  
22 scaffolds, we transferred the conditioned medium to the neuron cultures and evaluated neurite

1  
2  
3  
4 1 outgrowth. The conditioned media was obtained by collecting the 200  $\mu$ l culture media from  
5  
6 2 U2OS cells cultured on the control or CRISPRa-GDNF scaffolds for 3 days as mentioned in  
7  
8  
9 3 Section 2.11. Cortical neurons were isolated from P1 Sprague-Dawley rat pup brain cortices by  
10  
11 4 trypsin digestion at 37 °C for 15 min. After the suspension was passed through a 70  $\mu$ m cell  
12  
13  
14 5 strainer, the dissociated cortical neurons were seeded on aligned nanofiber scaffolds at 30,000  
15  
16 6 cells  $\text{cm}^{-2}$  in the conditioned medium at 37 °C [24]. DRG explants were harvested from P3 rat  
17  
18  
19 7 pups and all the meninges from the DRGs were taken off. Two DRG explants were seeded onto  
20  
21 8 each aligned nanofiber scaffolds with 1  $\text{cm}^2$  area. The cortical neurons and DRG explants were  
22  
23  
24 9 then cultured in the 200  $\mu$ l of the collected conditioned medium (Section 2.11) at 37 °C. After  
25  
26 10 cultured for 3 days, cortical neurons and DRG explants were fixed with 4% PFA at room  
27  
28  
29 11 temperature for 20 min. After washing in PBS for 3 times, cortical neurons and DRG explants  
30  
31 12 were permeabilized with 0.3% Triton X-100 followed by blocking with 10% goat serum for 1 h  
32  
33  
34 13 at room temperature. Thereafter, the samples were incubated with mouse anti- $\beta$ III-Tubulin (Tuj-  
35  
36 14 1, 1:1000 dilution) overnight at 4 °C, followed by incubation in goat anti-mouse Alexa Fluor 555  
37  
38  
39 15 secondary antibody for 2 h at room temperature. Cell nuclei were counterstained with DAPI.  
40  
41 16 Fluorescent images were acquired with an epifluorescence microscope (Leica DMI8) and  
42  
43 17 analyzed using Image J (NIH). At least 5 scaffolds of each group were used in this experiment.  
44  
45  
46 18 For cortical neurons, 10 images were taken using a 20 $\times$  objective for each scaffold and at least  
47  
48 19 90 cells were quantified for each group. For each DRG, the ten longest neurites were measured  
49  
50  
51 20 and averaged to determine the average neurite outgrowth length for each sample. At least 5 DRG  
52  
53 21 explants were analyzed from each group.  
54  
55  
56  
57  
58  
59  
60 23 *2.15. Statistical analysis*  
61  
62  
63  
64  
65


1  
2  
3  
4 1 All values were presented as mean  $\pm$  standard deviation (S.D). Outlier analysis was performed to  
5  
6 2 exclude significant outliers from the subsequent analyses. One-way ANOVA and Tukey's post-  
7  
8 3 hoc tests were used for samples that passed the homogeneity test. Otherwise, Kruskal–Wallis and  
9  
10 4 Mann – Whitney U test were used for pairwise analysis. Student's t-test was used to compare 2  
11  
12 5 independent samples. Tests were conducted with a 95% confidence interval ( $\alpha = 0.05$ ).  
13  
14  
15  
16  
17  
18  
19  
20

### 21 7 **3. Results**

#### 22 23 24 8 *3.1. Preparation and characterization of LbL coated PCL nanofibers*

25  
26  
27 9 The self-assembling peptides (SAP<sup>-</sup>, SAP<sup>+</sup>-RGD) were synthesized by Fmoc solid-phase  
28  
29 10 method. High-pressure liquid chromatography (HPLC) confirmed that the purity of the peptides  
30  
31 11 was 97.8% and 99.2%, respectively, and the mass spectrometry results assured the correct  
32  
33 12 molecular weight of these peptides (Fig. S1, S2). The PCL nanofibers were fabricated using an  
34  
35 13 electrospinning technique, and the LbL coating was then performed based on the strategy as  
36  
37 14 illustrated in Scheme 1. SAP<sup>-</sup>, the amphiphilic peptide bearing negative charges, was firstly  
38  
39 15 coated onto the PCL scaffolds by dip-coating, resulting in the negative surface charge.  
40  
41 16 Subsequently, the positively charged pDNA/PEIpro complexes and SAP<sup>+</sup>-RGD were coated.  
42  
43 17 This assembly process can also take place on the surface of PCL nanoparticles and was  
44  
45 18 confirmed by the sequential alternation of zeta-potential (Fig. S5). The strong hydrophobic  
46  
47 19 interactions between the aromatic side chains of the  $\beta$ -sheet SAP<sup>-</sup> and the PCL molecules  
48  
49 20 allowed the adsorption of SAP<sup>-</sup> onto the hydrophobic PCL surface, while the established  
50  
51 21 negatively charged surface further facilitated the adsorption of pDNA/PEIpro complexes and  
52  
53 22 subsequently SAP<sup>+</sup>-RGD through electrostatic interactions.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65






**Scheme 1. Schematic illustration of the layer-by-layer coating of SAPs on PCL nanofibers.**

As shown in the SEM images of the scaffolds (Fig. 1a), the SAP coatings did not mask the underlying fiber morphology. Specifically, the average fiber diameter of the plain PCL scaffolds was  $929 \pm 107$  nm, while that of the SAP<sup>-</sup>-coated scaffolds (“PCL@SAP<sup>-</sup>”) and SAP<sup>-</sup>/SAP<sup>+</sup>-RGD dual-coated scaffolds (“PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD”) was  $945 \pm 103$  nm and  $958 \pm 96$  nm, respectively. This suggests that the SAP coatings did not significantly alter the topography of the aligned fibers.

Surface wettability is one of the most important surface properties that affect the cellular response towards an implanted substrate, including cell attachment, spreading, and proliferation. The contact angles of PCL and PCL@SAP<sup>-</sup> were  $99.3 \pm 3.0^\circ$  and  $35.3 \pm 2.9^\circ$ , respectively. The significantly increased hydrophilicity suggests the successful coating of the negatively charged SAP<sup>-</sup>. Subsequently, the adsorption of the positively charged PEI complexes and then the coating of SAP<sup>+</sup>-RGD resulted in a slightly increased contact angle ( $52.3 \pm 5.2^\circ$ ). The contact angles of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 the SAP-coated PCL scaffolds did not change significantly after incubation in phosphate-  
2 buffered saline (PBS) for at least 7 days (Fig. S6), indicating the good stability of SAP  
3 modification. Furthermore, we also characterized these scaffolds by comparing typical chemical  
4 bonds before and after SAP coating. Fourier transform infrared (FT-IR) spectroscopy  
5 measurements revealed plain PCL scaffolds exhibited the absorption peak at  $1720\text{ cm}^{-1}$ , which is  
6 indicative of the  $\text{-C=O}$  stretching vibration of PCL (Fig. S7). After  $\text{SAP}^-$  coating, two strong  
7 peaks at  $3293\text{ cm}^{-1}$  and  $1635\text{ cm}^{-1}$  were observed, and these were attributed to the  $\text{-NH-}$   
8 stretching vibration and  $\text{-NH}_2$  bending vibration of  $\text{SAP}^-$ , respectively. These findings  
9 collectively suggest that the SAP was successfully coated onto the PCL nanofibers.



10




1  
2  
3  
4 **Fig. 1. Characterization of SAP-coated scaffolds.** a) SEM images and photographs of water  
5  
6 contact angles of the SAP-coated scaffolds; scale bar = 10  $\mu\text{m}$ . b) Fiber diameters ( $n = 3$ ) and c)  
7  
8 water contact angles of the SAP-coated scaffolds ( $n = 3$ ); <sup>\*\*\*</sup> $p < 0.001$ , “NS” indicates “no  
9  
10 significance”.  
11  
12  
13  
14  
15  
16  
17

### 18 3.2. SAP-coated scaffolds mediated efficient loading and sustained release of pDNA/PEIpro 19 20 21 complexes 22 23

24 Polyethylenimine (PEI), a cationic polymer, is a widely used and cost-effective reagent for  
25  
26 gene delivery. However, the N-propionyl groups in PEI molecules may reduce the number of  
27  
28 protonatable nitrogen residues and hinder the nucleic acid condensation and endosomal escape.  
29  
30 Therefore, the deacylated PEI, commercially known as PEIpro, was chosen for this work and  
31  
32 shown to be superior for the mammalian cells [25]. As shown in Fig. S8, no significant  
33  
34 difference was observed in the particle size and zeta potential of PEIpro/pDNA complexes with  
35  
36 an increase in N/P ratio. Thus, the complexes of N/P = 8 with moderate positive charge ( $+8.4 \pm$   
37  
38  $1.1$  mV) and relatively small size ( $37.78 \pm 11.06$  nm) were chosen for all subsequent  
39  
40 experiments. To visualize the distribution of the pDNA/PEIpro complexes on the scaffolds,  
41  
42 fluorescently-tagged pDNA, MFP488-pDNA, was used. As shown in Fig. 2a, a uniform  
43  
44 distribution of MFP488-pDNA/PEIpro complexes could be identified on the aligned fiber  
45  
46 substrates. Specifically, the SAP-coated fibers, both PCL@SAP<sup>-</sup> and PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD,  
47  
48 demonstrated significantly higher affinity to the complexes, and the loading efficiency of plain  
49  
50 PCL, PCL@SAP<sup>-</sup>, and PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds was  $82.9 \pm 2.4\%$ ,  $97.2 \pm 2.6\%$ , and  
51  
52  $93.4 \pm 3.7\%$ , respectively (Fig. 2b). We next investigated the release kinetics of the complexes  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 from the scaffolds that were incubated in PBS at 37 °C (Fig. 2c). As compared to the plain PCL  
2 scaffolds in which the pDNA/PEIpro complexes were loosely entrapped, the SAP-coated  
3 scaffolds exhibited significantly smaller initial burst release and slower subsequent release of the  
4 complexes. These SAP-coated scaffolds were capable of releasing pDNA/PEIpro continuously  
5 for at least a week. Notably, the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds demonstrated similar  
6 loading efficiency and release rate as that of the PCL@SAP<sup>-</sup> scaffolds, indicating that the  
7 subsequent coating of SAP<sup>+</sup>-RGD did not significantly affect the loading and release profile of  
8 the complexes. It is believed that the electrostatic interactions between the negatively charged  
9 SAP<sup>-</sup> and positively charged pDNA/PEIpro complexes may help to immobilize these complexes  
10 on the scaffolds and slow down the release. In contrast, the faster release of complexes from the  
11 plain PCL scaffolds may be due to the lack of such stabilizing mechanisms. Moreover, this  
12 platform constructed by electrostatic interactions is also capable of trapping other complexes,  
13 which include some of the commonly used RNA/Lipofectamine, protein/Lipofectamine, and  
14 pDNA/semiconducting polymer nanoparticles (SPNs) (Fig. S9). Hence, the platform is believed  
15 to be an effective approach for the delivery of various positively charged nano-complexes.



**Fig. 2. Characterization of the loading and release profiles of the pDNA/PEIpro complexes.**


a) Fluorescent images show a uniform distribution of MFP488- pDNA/PEIpro complexes on

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 aligned fiber substrates. Scale bar = 100  $\mu\text{m}$  (Insert: 10  $\mu\text{m}$ ). b) Loading efficiency of  
2 pDNA/PEIpro complexes on the scaffolds (n = 3). c) Cumulative release profile of  
3 pDNA/PEIpro complexes from scaffolds over 7 days (n = 5).

### 3.3. SAP-coated scaffolds promoted cell adhesion and proliferation

6 To better visualize the nanofibers and cell-substrate interactions, Rhodamine B was linked to  
7 the N-terminus of SAP<sup>-</sup>. We subsequently examined the effect of SAP coating on cell adhesion  
8 by seeding U2OS cells on the scaffolds. As shown in Fig. 3a, after 48 h of culture, only a limited  
9 number of cells were observed on the plain PCL scaffolds, while significantly more cells were  
10 observed on the PCL@SAP<sup>-</sup> and PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds (Fig. 3b), indicating the  
11 improved cell affinity. Similarly, when the cells were cultured in the serum-free medium, the  
12 RGD-bearing scaffolds still demonstrated the best cell adhesion performance (Fig. 3c),  
13 suggesting that the cells bound directly to RGD instead of the serum proteins that were present in  
14 the culture medium. Other than U2OS, these SAP-coated scaffolds can also support the adhesion  
15 and spreading of numerous cells, such as human mesenchymal stem cells (hMSCs) and human  
16 neural progenitor cells (hNPCs) (Fig. S10). Besides, enhanced cell proliferation was also  
17 observed on the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds (Fig. S11). When these SAP-coated  
18 scaffolds were subcutaneously implanted, they showed better biocompatibility and cell  
19 infiltration *in vivo* (Fig. S12).





**Fig. 3. SAP coating enhanced cell adhesion on the scaffolds.** a) Representative fluorescent images of U2OS cells on different scaffolds; scale bar = 50  $\mu\text{m}$ . Average cell number per  $\text{mm}^2$  of U2OS cells after 48 h of culture on scaffolds in b) full medium and c) FBS-free medium for 2 days, respectively (n = 3); \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

### 3.4. SAP-coated scaffolds facilitated efficient localized gene transfection

1 To facilitate the characterization of positive transfection using the CRISPR system, the  
2 reporter gene, GFP, was fused to the Cas9 expression cassette [21], and the Cas9-GFP plasmids  
3 were used for transfection. As shown in Fig. 4a, the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD group  
4 demonstrated the greatest number of GFP-positive cells and the highest intensity of green  
5 fluorescence. In comparison, the PCL@SAP<sup>-</sup> group showed a smaller number of GFP-positive  
6 cells, and the green fluorescence was seldom observed in the absence of SAP coating (“PCL”).  
7 The quantitative results confirmed that PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD yielded 54.6 GFP<sup>+</sup> cells per  
8 mm<sup>2</sup>, whereas PCL@SAP<sup>-</sup> and plain PCL only led to 14.4 and 0.7 GFP<sup>+</sup> cells per mm<sup>2</sup>,  
9 respectively (Fig. 4b). Meanwhile, although the total cell number on the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-  
10 RGD scaffold was significantly higher than the others owing to the enhanced adhesion, this  
11 group still showed the best GFP<sup>+</sup> percentage (16.1%) among the three groups (Fig. 4c), which is  
12 similar to the efficiency of the bolus transfection (18.2%). Furthermore, the gene delivery  
13 efficiency was dose-dependent (Fig. S13). Specifically, we found that 4 μg was the optimal  
14 amount of plasmid as we started to see toxicity and lower efficiency at 6 μg. We also attempted  
15 to assess the transfection efficiency of hNPCs, which are more difficult to be transfected, by  
16 seeding these cells on the scaffolds. Correspondingly, we were only able to achieve a much  
17 lower transfection efficiency of 9.3% by scaffold-mediated delivery and 11.3% by bolus delivery  
18 (Fig. S14).





1  
2 **Fig. 4. SAP-coated scaffolds enhanced the efficiency of Cas9-GFP transfection in**  
3 **mammalian cells.** a) Representative fluorescent images of U2OS cells on different scaffolds;  
4 scale bar = 50  $\mu$ m. Quantification of b) average number of Cas9-GFP<sup>+</sup> cells per mm<sup>2</sup> and c)  
5 transfection efficiency based on fluorescent images (n = 3); \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , “NS”  
6 indicates “no significance”.


1  
2  
3  
4 1 3.5. Scaffold-mediated CRISPRa system promoted endogenous gene-activation in mammalian  
5  
6 2 cells  
7  
8  
9

10 3 Having established the ability of the SAP-coated scaffolds to facilitate localized gene  
11  
12 4 transfection of mammalian cells, we next examined their specific performance in the delivery of  
13  
14 5 the CRISPRa system and constructed a CRISPRa system targeting hGDNF gene (Fig. 5a). Here,  
15  
16 6 we aimed to utilize GDNF as a proof of concept because the protein secreted is easily detected  
17  
18 7 and quantified, making it a straightforward evaluation of CRISPRa system delivery. The  
19  
20 8 sequences of sgRNAs reported in the literature were ligated into sgRNA expressing vectors and  
21  
22 9 confirmed by DNA sequencing (Table S1, Fig. S15) [26]. We first evaluated the sgRNAs in  
23  
24 10 U2OS cells via co-delivery of sgRNA and dCas9-VPR (i.e., dCas9 fused with a potent tripartite  
25  
26 11 activator, VP64, p65AD and Rta [22]) expressing vectors by bolus transfection, and the  
27  
28 12 treatment significantly increased the mRNA expression of GDNF (Fig. 5b). Meanwhile, it has  
29  
30 13 been reported that multiple sgRNA-dCas9-VP64 complexes can bind to a single promoter,  
31  
32 14 thereby acting synergistically and more efficiently [27]. This synergistic effect was also observed  
33  
34 15 in our experiments and hence the cocktail of sgRNAs (sg01 + 02 + 03) was used in the  
35  
36 16 experiments hereafter.

37  
38  
39 17 Subsequently, these pDNA/PEIpro complexes of both sgRNAs and dCas9-VPR expressing  
40  
41 18 vectors were loaded onto the SAP-coated scaffolds, and the U2OS cells were seeded and  
42  
43 19 cultured on the scaffolds. Compared to the non-treated control group, scaffold-mediated  
44  
45 20 transfection of CRISPRa-GDNF resulted in substantial upregulation of GDNF mRNA expression  
46  
47 21 (Fig. 5c). In order to quantify the secretion of GDNF, ELISA was used for the assay of cell  
48  
49 22 culture medium at preset time points. Although the concentration of GDNF in the medium did  
50  
51 23 not change significantly after 24 h, the cells started to produce robust levels of GDNF after 48 h  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (Fig. 5d), and the cumulative amount of GDNF secreted in the CRISPRa-GDNF group was also  
 2 higher than that in the control group (Fig. 5e). However, due to the fast proliferation rate, the  
 3 cells covered near 90% area of the scaffolds after 72 h, and hence the monitoring of GDNF  
 4 expression had to be terminated. These results indicated that the CRISPRa system could be  
 5 loaded onto the scaffolds and delivered to recipient cells for gene engineering.




6  
7 **Fig. 5. SAP-coated scaffolds mediated the delivery of CRISPR/dCas9 based gene activation**  
 8 **(CRISPRa-GDNF) system to enhance GDNF mRNA and protein expressions.** a) Schematic  
 9 representation of the CRISPRa-GDNF system. b) Relative expression of GDNF mRNA in U2OS  
 10 cells in which the individual or combinations of sgRNAs were co-delivered with dCas9-VPR (n  
 11 = 3). c) Relative expression of GDNF mRNA, d) GDNF concentration in culture medium at

1 different time points and e) cumulative GDNF protein expression over 3 days in U2OS cells  
2 seeded onto the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffolds (n = 3); \*  $p < 0.05$ , \*\*  $p < 0.01$ .

### 3 *3.6. Scaffold-mediated CRISPRa-GDNF system promoted neurite outgrowth*

4 To further investigate the functional effect of the scaffold-mediated CRISPRa-GDNF  
5 system, the ideal experiment would have been a co-culture experiment of U2OS cells and  
6 neurons. However, the complexity of keeping both cells alive in the same medium was difficult.  
7 The U2OS cells had a high proliferative rate on the scaffolds and would compete for nutrients  
8 with the neurons, without adding more media and supplements that might mask the effect of the  
9 secreted GDNF. Therefore, we collected the media containing GDNF that were secreted by the  
10 U2OS cells seeded on the CRISPRa-functionalized scaffold after 3 days (i.e. conditioned  
11 medium), and tested for the bioactivity of the secreted GDNF using primary neurons.  
12 Specifically, we transferred the conditioned medium to rat cortical neurons and dorsal root  
13 ganglia (DRGs) explants that were cultured on the nanofiber scaffolds for another 3 days. Fig. 6a  
14 and b show the representative fluorescent images of cortical neurons and DRGs cultured in  
15 culture medium from control and CRISPRa-GDNF scaffolds, respectively, and the neurite  
16 outgrowth along the long axis of fibers could be observed. Quantitative analysis confirmed that  
17 the CRISPRa-GDNF conditioned medium significantly enhanced neurite outgrowth in both  
18 cortical neurons and DRG explants (Fig. 6c and d).



**Fig. 6. Scaffold-mediated CRISPRa-GDNF system promoted neurite outgrowth.**

Representative fluorescent images of a) rat cortical neurons and b) DRG explants cultured in control culture medium and CRISPRa-GDNF conditioned medium, respectively. White arrows represent fiber directions while yellow arrows indicate neurites. Quantification of the c) neurite length for cortical neurons (at least 100 neurites from 5 scaffolds each group) and d) average length of 10 longest neurites for DRG explants ( $n = 5$  for control,  $n = 6$  for CRISPRa-GDNF);  $p < 0.05$ ,  $** p < 0.01$ .

#### 4. Discussion

Biodegradable polymers, such as PCL, are widely used for the fabrication of tissue engineering scaffolds. The chemical and biological stability of PCL makes it difficult for surface

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 modification. Therefore, simple noncovalent binding are methods usually accompanied by a  
2 quick loss of the coating layers due to insufficient interfacial interactions. On the other hand, the  
3 chemical modifications typically involve complex, laborious, and environmentally unfriendly  
4 chemical synthesis. Utilizing the hydrophobicity of PCL, the SAP coating can alter the surface  
5 charge of PCL fiber scaffolds. This approach offers a high level of customization as different  
6 peptides can be designed and incorporated into the coating according to specific needs (eg:  
7 surfaces with a positive charge, negative charge, cell adhesive peptides, etc). These  
8 functionalized SAPs can be coated onto the fibers alone or as a cocktail, and the ratio of different  
9 peptides can be adjusted easily. Therefore, the SAP coating is easy-to-implement and sufficiently  
10 stable to perform more than one role (eg: immobilization of biomolecules on the surface and  
11 support specific cell adhesion).

12 By altering the surface charge, the PCL@SAP<sup>-</sup> group demonstrated improved cell adhesion  
13 as compared to plain PCL (Fig. 3), similar to the effect of gas-plasma treatment on cell culture  
14 dishes, which makes them more hydrophilic and negatively-charged [28]. We conjugated RGD  
15 to the SAP<sup>+</sup> as the RGD peptide can be recognized by the integrin subsets and as such may  
16 further enhance cell adhesion and spreading (Fig. 3) [29]. Moreover, the SAP backbone can also  
17 be conjugated with other peptide sequences other than RGD, such as laminin-derived peptides  
18 (IKVAV, YIGSR), N-cadherin mimetic peptide (HAVDI), and Wnt mimetic ligand (MDGECL),  
19 thereby offering superb flexibility for various applications [30]. For example, the laminin-  
20 derived peptides can be conjugated to enhance neuronal adhesion and neurite outgrowth for  
21 neural tissue engineering. Therefore, we herein demonstrate a convenient method for the surface  
22 modification of PCL fibers and a promising platform for the investigation of cell-substrate  
23 interactions.

1  
2  
3  
4 1 In this study, the scaffolds were capable of delivering the CRISPR/dCas9 system in a non-  
5  
6 2 viral manner, which is safer as compared to virus-mediated delivery that raises biosafety  
7  
8 3 concerns. While non-viral polyplexes usually cause some cytotoxicity issues, an optimized  
9  
10 4 delivery method can keep the toxicity under an acceptable level. Here, the cells grew with a high  
11  
12 5 proliferation rate and covered over 90% scaffold area within 3 days, suggesting that the cell  
13  
14 6 viability was acceptable. Such fiber scaffolds also provide more localized and sustained delivery  
15  
16 7 of the CRISPR/dCas9 system than existing methods. In particular, the scaffold-mediated delivery  
17  
18 8 approach ensures localized availability of drugs, which may reduce systemic side effects that is  
19  
20 9 often prominent in systemic delivery approaches. Previous *in vivo* studies showed that similar  
21  
22 10 approaches with scaffold-mediated gene delivery platforms locally released the complexes into  
23  
24 11 the tissues within 300  $\mu\text{m}$  from the edge of the scaffolds [31, 32]. Published results showed that  
25  
26 12 the complexes immobilized on the scaffolds were directly uptaken by the cells from the scaffold  
27  
28 13 surface [14, 18]. Here, Cas9-GFP signals in cells were observed within two days, where the  
29  
30 14 cumulative release was only less than 5%, suggesting that the cells also took up the complexes  
31  
32 15 directly from the scaffold surface. Although there were some larger polyplex aggregates on the  
33  
34 16 scaffold, cellular uptake was not affected as around  $97.3 \pm 2.4$  % cells were found to contain the  
35  
36 17 labelled polyplexes within the cell body (Fig. S16). Furthermore, the modified nanofiber  
37  
38 18 scaffolds can also provide topographical cues for tissue regeneration. In addition to  
39  
40 19 CRISPR/dCas9 system, the coating is expected to be able to immobilize other biomolecules such  
41  
42 20 as nucleic acids (siRNA, miRNA, plasmids) and proteins on the scaffold surfaces.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 21 In addition to the adsorption of CRISPR complexes on the SAP coated nanofibers, the  
55  
56 22 enhanced cellular uptake of the complexes can also be attributed to the increased rate of cell  
57  
58 23 proliferation. The transfection efficiency of the complexes might be affected by the rate of cell  
59  
60  
61  
62  
63  
64  
65

1 proliferation during which the cell membranes undergo disruption and reconstruction [33]. Here,  
2 the U2OS cells proliferated most quickly on the PCL@SAP<sup>-</sup>@SAP<sup>+</sup>-RGD scaffold (Fig. S8),  
3 thereby possibly leading to the enhanced uptake of pDNA/PEIpro complexes. However, we did  
4 not achieve desirable transfection efficiency with hNPCs, a more realistic model, even by bolus  
5 delivery (Fig. S14). One major limitation of this platform is that the transfection efficiency may  
6 be affected by the effectiveness and efficiency of the delivery vehicles. Currently, low  
7 transfection efficiency is a common problem when transfecting the difficult-to-transfect primary  
8 cells, such as hNPCs, hMSCs and dermal fibroblasts [34, 35]. Although PEIpro was shortlisted  
9 as the most efficient commercially available transfection reagent through our initial optimization  
10 studies (Fig. S14), substituting PEIpro with a better-designed delivery vehicle may further  
11 improve the gene delivery efficiency of the scaffold to the hNPCs and neural cells in general. In  
12 addition, ribonucleoprotein may be a better format than pDNA in terms of CRISPR complex  
13 delivery due to less off-target effects and higher efficiency. As delivery of CRISPR complexes to  
14 primary neural cells, particularly post-mitotic neurons, may be challenging, a combination of the  
15 improved format (such as ribonucleoprotein) and delivery vehicle will be needed to achieve  
16 better results. Furthermore, a comprehensive *in vivo* evaluation of both transfection and gene  
17 activation for tissue regeneration will be needed for future pre-clinical studies.

18 In this study, we only targeted a single gene (GDNF) as a proof of concept. By delivering  
19 CRISPRa systems through SAP-coated nanofibers, GDNF expression was activated and hence  
20 leading to the production of bioactive GDNF by cells, as demonstrated by the neurite outgrowth  
21 assays. While the main objective of this study is to evaluate the ability of the coating to deliver  
22 CRISPRa systems, the level of secreted GDNF ( $1.0 \times 10^{-3}$  pg/cell/24h) is comparable to the  
23 approaches that directly deliver GDNF transgene ( $4.8 \times 10^{-4}$  to  $1.7 \times 10^{-1}$  pg/cell/24h) and was



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 effective in stimulating neurite outgrowth [36-40]. GDNF has already been well-established to  
2 enhance neurite outgrowth of rat DRG explants and cortical neurons. Hence, we did not include  
3 the GDNF-containing media as a positive control to save resources. In the literature, GDNF  
4 added at a concentration range of 1 to 100 ng/ml induced 1.5 to 7-folds increase in neurite length  
5 of the rat DRG in a dose-dependent manner [41-44]. Similarly, neurite length of rat cortical  
6 neurons increased 1.2 to 3-folds in the presence of 0.1 to 100 ng/ml GDNF in a dose-dependent  
7 manner [45-47]. The increase in neurite length of DRG and cortical neurons in our experiment  
8 were about 1.5-folds and 2-folds of the control respectively, which are within the range of the  
9 published results. A small amount of GDNF as little as 70 pg/ml could stimulate neurite  
10 outgrowth of spinal neurons [48].

11 In addition, the CRISPRa system is also capable of targeting multiple genes, requiring only  
12 additional sgRNAs. Future works may extend the application of the CRISPRa systems-loaded  
13 platform to relevant primary cells, such as glia and meningeal cells, which could be ideal targets  
14 *in vivo* to secrete GDNF locally to enhance nerve regeneration. This ability of selective gene  
15 upregulation provides a promising strategy to direct stem or progenitor cell differentiation for  
16 regenerative medicine applications [49]. For example, these scaffolds are expected to be capable  
17 of localized delivery of CRISPR/dCas9 to direct neuronal differentiation of stem cells through  
18 the activation of transcription factors, which will contribute to neural regeneration as well [50,  
19 51]. Besides the CRISPRa system, this scaffold-mediated CRISPR delivery system is also  
20 suitable for CRISPR knockout (CRISPRko) and CRISPRi systems when the corresponding  
21 sgRNAs and Cas9 or dCas9 expressing vectors are utilized.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **5. Conclusion**

2 In summary, we synthesized two amphiphilic SAPs with opposite net charges, SAP<sup>-</sup> and  
3 SAP<sup>+</sup>-RGD. The SAP was first coated onto PCL nanofibers through strong hydrophobic  
4 interactions, and the pDNA/PEI<sup>pro</sup> complexes and SAP<sup>+</sup>-RGD were then easily absorbed via  
5 electrostatic interactions. The SAP-coated scaffolds facilitated efficient loading and sustained  
6 release of the pDNA complexes, while similar amount of pDNA complexes were completely  
7 released from plain PCL scaffolds within 7 days. Meanwhile, the SAP coating effectively  
8 enhanced cell adhesion and proliferation, even in the absence of serum proteins (p < 0.0001).  
9 Therefore, these scaffolds were utilized for the localized delivery of the CRISPR/dCas9 system,  
10 which activated GDNF expression in mammalian cells and produced GDNF (1.0×10<sup>-3</sup>  
11 pg/cell/24h). The secreted GDNF retained its bioactivity and promoted neurite outgrowth, as  
12 evidenced by the twice longer neurites than the non-treated groups. All these promising results  
13 indicate that LbL SAP-coated nanofibers provide a useful tool for non-viral genome editing.  
14 Together with the continuously developing CRISPR techniques, such scaffolds demonstrate  
15 great potential in tissue regeneration.

16  
17 **Competing interest**

18 The authors declare no conflict of interest.

19  
20 **Acknowledgment**

21 This research is supported by the A\*Star BMRC International Joint Grant – Singapore-China  
22 Joint Research Program (Project no. 1610500024) and MOE AcRF Tier 1 Grant (Project No:

1  
2  
3  
4 1 RG148/14) awarded to SYC. The authors would like to thank Prof Hai-quan Mao (Johns  
5  
6  
7 2 Hopkins University), Prof Kam Leong and Dr Hongxia Wang (Columbia University), Dr  
8  
9 3 Chuntao Liu (Sun Yat-sen University), Na Zhang, Junquan Lin, and William Ong (Nanyang  
10  
11 4 Technological University) for insightful suggestion and discussion, and Prof Sierin Lim  
12  
13  
14 5 (Nanyang Technological University) for providing the E. Coli culture facilities.  
15  
16  
17  
18 6  
19

## 20 7 **References**

- 22 8 [1] P.D. Hsu, E.S. Lander, F. Zhang, Development and applications of CRISPR-Cas9 for  
23 9 genome engineering, *Cell* 157(6) (2014) 1262-78.  
24 10 [2] D.B. Cox, R.J. Platt, F. Zhang, Therapeutic genome editing: prospects and challenges, *Nat*  
25 11 *Med* 21(2) (2015) 121-31.  
26 12 [3] P. Perez-Pinera, D.D. Kocak, C.M. Vockley, A.F. Adler, A.M. Kabadi, L.R. Polstein, P.I.  
27 13 Thakore, K.A. Glass, D.G. Ousterout, K.W. Leong, F. Guilak, G.E. Crawford, T.E. Reddy, C.A.  
28 14 Gersbach, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, *Nat*  
29 15 *Methods* 10(10) (2013) 973-6.  
30 16 [4] M.H. Hanewich-Hollatz, Z. Chen, L.M. Hochrein, J. Huang, N.A. Pierce, Conditional guide  
31 17 RNAs: programmable conditional regulation of CRISPR/Cas function in bacterial and  
32 18 mammalian cells via dynamic RNA nanotechnology, *ACS central science* 5(7) (2019) 1241-  
33 19 1249.  
34 20 [5] M.F. La Russa, L.S. Qi, The New State of the Art: Cas9 for Gene Activation and Repression,  
35 21 *Mol Cell Biol* 35(22) (2015) 3800-9.  
36 22 [6] M.H. Larson, L.A. Gilbert, X. Wang, W.A. Lim, J.S. Weissman, L.S. Qi, CRISPR  
37 23 interference (CRISPRi) for sequence-specific control of gene expression, *Nature protocols* 8(11)  
38 24 (2013) 2180.  
39 25 [7] P. Perez-Pinera, D.D. Kocak, C.M. Vockley, A.F. Adler, A.M. Kabadi, L.R. Polstein, P.I.  
40 26 Thakore, K.A. Glass, D.G. Ousterout, K.W. Leong, RNA-guided gene activation by CRISPR-  
41 27 Cas9-based transcription factors, *Nature methods* 10(10) (2013) 973.  
42 28 [8] S.M. Czerniecki, N.M. Cruz, J.L. Harder, R. Menon, J. Annis, E.A. Otto, R.E. Gulieva, L.V.  
43 29 Islas, Y.K. Kim, L.M. Tran, T.J. Martins, J.W. Pippin, H. Fu, M. Kretzler, S.J. Shankland, J.  
44 30 Himmelfarb, R.T. Moon, N. Paragas, B.S. Freedman, High-Throughput Screening Enhances  
45 31 Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated  
46 32 Multidimensional Phenotyping, *Cell Stem Cell* 22(6) (2018) 929-940 e4.  
47 33 [9] H.X. Wang, M. Li, C.M. Lee, S. Chakraborty, H.W. Kim, G. Bao, K.W. Leong,  
48 34 CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and  
49 35 Opportunities for Nonviral Delivery, *Chem Rev* 117(15) (2017) 9874-9906.  
50 36 [10] D.G. Tamay, T. Dursun Usal, A.S. Alagoz, D. Yucel, N. Hasirci, V. Hasirci, 3D and 4D  
51 37 Printing of Polymers for Tissue Engineering Applications, *Front Bioeng Biotechnol* 7 (2019)  
52 38 164.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


- 1  
2  
3  
4 1 [11] A. Cipitria, A. Skelton, T.R. Dargaville, P.D. Dalton, D.W. Hutmacher, Design, fabrication  
5 2 and characterization of PCL electrospun scaffolds—a review, *Journal of Materials Chemistry*  
6 3 21(26) (2011) 9419-9453.
- 8 4 [12] H.J. Diao, W.C. Low, U. Milbreta, Q.R. Lu, S.Y. Chew, Nanofiber-mediated microRNA  
9 5 delivery to enhance differentiation and maturation of oligodendroglial precursor cells, *J Control*  
10 6 *Release* 208 (2015) 85-92.
- 11 7 [13] W.C. Low, P.O. Rujitanaroj, D.K. Lee, P.B. Messersmith, L.W. Stanton, E. Goh, S.Y.  
12 8 Chew, Nanofibrous scaffold-mediated REST knockdown to enhance neuronal differentiation of  
14 9 stem cells, *Biomaterials* 34(14) (2013) 3581-90.
- 15 10 [14] W.H. Chooi, W. Ong, A. Murray, J. Lin, D. Nizetic, S.Y. Chew, Scaffold mediated gene  
16 11 knockdown for neuronal differentiation of human neural progenitor cells, *Biomater Sci* 6(11)  
17 12 (2018) 3019-3029.
- 19 13 [15] J. Lin, D. Anopas, U. Milbreta, P.H. Lin, J.S. Chin, N. Zhang, S.K. Wee, A. Tow, W.T.  
20 14 Ang, S.Y. Chew, Regenerative rehabilitation: exploring the synergistic effects of rehabilitation  
21 15 and implantation of a bio-functional scaffold in enhancing nerve regeneration, *Biomater Sci*  
22 16 7(12) (2019) 5150-5160.
- 24 17 [16] W. Ong, J. Lin, M.E. Bechler, K. Wang, M. Wang, C. Ffrench-Constant, S.Y. Chew,  
25 18 Microfiber drug/gene delivery platform for study of myelination, *Acta Biomater* 75 (2018) 152-  
26 19 160.
- 27 20 [17] H.J. Diao, W.C. Low, Q.R. Lu, S.Y. Chew, Topographical effects on fiber-mediated  
28 21 microRNA delivery to control oligodendroglial precursor cells development, *Biomaterials* 70  
29 22 (2015) 105-14.
- 31 23 [18] J.S. Chin, W.H. Chooi, H. Wang, W. Ong, K.W. Leong, S.Y. Chew, Scaffold-mediated non-  
32 24 viral delivery platform for CRISPR/Cas9-based genome editing, *Acta Biomater* 90 (2019) 60-70.
- 33 25 [19] S. Jo, S.M. Kang, S.A. Park, W.D. Kim, J. Kwak, H. Lee, Enhanced adhesion of  
34 26 preosteoblasts inside 3D PCL scaffolds by polydopamine coating and mineralization, *Macromol*  
35 27 *Biosci* 13(10) (2013) 1389-95.
- 37 28 [20] L. Li, S. Hu, X. Chen, Non-viral delivery systems for CRISPR/Cas9-based genome editing:  
38 29 Challenges and opportunities, *Biomaterials* 171 (2018) 207-218.
- 39 30 [21] F.A. Ran, P.D. Hsu, J. Wright, V. Agarwala, D.A. Scott, F. Zhang, Genome engineering  
40 31 using the CRISPR-Cas9 system, *Nat Protoc* 8(11) (2013) 2281-2308.
- 42 32 [22] A. Chavez, J. Scheiman, S. Vora, B.W. Pruitt, M. Tuttle, P.R.I. E, S. Lin, S. Kiani, C.D.  
43 33 Guzman, D.J. Wiegand, D. Ter-Ovanesyan, J.L. Braff, N. Davidsohn, B.E. Housden, N.  
44 34 Perrimon, R. Weiss, J. Aach, J.J. Collins, G.M. Church, Highly efficient Cas9-mediated  
45 35 transcriptional programming, *Nat Methods* 12(4) (2015) 326-8.
- 47 36 [23] A. Murray, A. Letourneau, C. Canzonetta, E. Stathaki, S. Gimelli, F. Sloan-Bena, R.  
48 37 Abrehart, P. Goh, S. Lim, C. Baldo, F. Dagna-Bricarelli, S. Hannan, M. Mortensen, D. Ballard,  
49 38 D. Syndercombe Court, N. Fusaki, M. Hasegawa, T.G. Smart, C. Bishop, S.E. Antonarakis, J.  
50 39 Groet, D. Nizetic, Brief report: isogenic induced pluripotent stem cell lines from an adult with  
51 40 mosaic down syndrome model accelerated neuronal ageing and neurodegeneration, *Stem Cells*  
52 41 33(6) (2015) 2077-84.
- 54 42 [24] N. Zhang, U. Milbreta, J.S. Chin, C. Pinese, J. Lin, H. Shirahama, W. Jiang, H. Liu, R. Mi,  
55 43 A. Hoke, W. Wu, S.Y. Chew, Biomimicking Fiber Scaffold as an Effective In Vitro and In Vivo  
56 44 MicroRNA Screening Platform for Directing Tissue Regeneration, *Adv Sci (Weinh)* 6(9) (2019)  
57 45 1800808.

- 1  
2  
3  
4 1 [25] L. Delafosse, P. Xu, Y. Durocher, Comparative study of polyethylenimines for transient  
5 2 gene expression in mammalian HEK293 and CHO cells, *J Biotechnol* 227 (2016) 103-111.  
6 3 [26] S. Konermann, M.D. Brigham, A.E. Trevino, J. Joung, O.O. Abudayyeh, C. Barcena, P.D.  
7 4 Hsu, N. Habib, J.S. Gootenberg, H. Nishimasu, O. Nureki, F. Zhang, Genome-scale  
8 5 transcriptional activation by an engineered CRISPR-Cas9 complex, *Nature* 517(7536) (2015)  
9 6 583-8.  
10 7 [27] M.L. Maeder, S.J. Linder, V.M. Cascio, Y. Fu, Q.H. Ho, J.K. Joung, CRISPR RNA-guided  
11 8 activation of endogenous human genes, *Nat Methods* 10(10) (2013) 977-9.  
12 9 [28] M.J. Lerman, J. Lembong, S. Muramoto, G. Gillen, J.P. Fisher, The Evolution of  
13 10 Polystyrene as a Cell Culture Material, *Tissue Eng Part B Rev* 24(5) (2018) 359-372.  
14 11 [29] E. Ruoslahti, RGD and other recognition sequences for integrins, *Annu Rev Cell Dev Biol*  
15 12 12 (1996) 697-715.  
16 13 [30] N. Huettner, T.R. Dargaville, A. Forget, Discovering Cell-Adhesion Peptides in Tissue  
17 14 Engineering: Beyond RGD, *Trends Biotechnol* 36(4) (2018) 372-383.  
18 15 [31] L.H. Nguyen, M. Gao, J. Lin, W. Wu, J. Wang, S.Y. Chew, Three-dimensional aligned  
19 16 nanofibers-hydrogel scaffold for controlled non-viral drug/gene delivery to direct axon  
20 17 regeneration in spinal cord injury treatment, *Sci Rep* 7 (2017) 42212.  
21 18 [32] C. Pinese, J. Lin, U. Milbreta, M. Li, Y. Wang, K.W. Leong, S.Y. Chew, Sustained delivery  
22 19 of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene  
23 20 silencing, *Acta Biomater* 76 (2018) 164-177.  
24 21 [33] S. Chernousova, M. Epple, Live-cell imaging to compare the transfection and gene silencing  
25 22 efficiency of calcium phosphate nanoparticles and a liposomal transfection agent, *Gene Ther*  
26 23 24(5) (2017) 282-289.  
27 24 [34] Y. Wang, L. Wang, Y. Zhu, J. Qin, Human brain organoid-on-a-chip to model prenatal  
28 25 nicotine exposure, *Lab Chip* 18(6) (2018) 851-860.  
29 26 [35] O. Gresch, L. Altrogge, Transfection of difficult-to-transfect primary mammalian cells,  
30 27 *Methods Mol Biol* 801 (2012) 65-74.  
31 28 [36] A. Sajadi, J.C. Bensadoun, B.L. Schneider, C. Lo Bianco, P. Aebischer, Transient striatal  
32 29 delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral  
33 30 model of Parkinson disease, *Neurobiol Dis* 22(1) (2006) 119-29.  
34 31 [37] M. Suzuki, J. McHugh, C. Tork, B. Shelley, A. Hayes, I. Bellantuono, P. Aebischer, C.N.  
35 32 Svendsen, Direct muscle delivery of GDNF with human mesenchymal stem cells improves  
36 33 motor neuron survival and function in a rat model of familial ALS, *Mol Ther* 16(12) (2008)  
37 34 2002-10.  
38 35 [38] M. Suzuki, J. McHugh, C. Tork, B. Shelley, S.M. Klein, P. Aebischer, C.N. Svendsen,  
39 36 GDNF secreting human neural progenitor cells protect dying motor neurons, but not their  
40 37 projection to muscle, in a rat model of familial ALS, *PLoS One* 2(8) (2007) e689.  
41 38 [39] A.A. Akhtar, G. Gowing, N. Kobritz, S.E. Savinoff, L. Garcia, D. Saxon, N. Cho, G. Kim,  
42 39 C.M. Tom, H. Park, G. Lawless, B.C. Shelley, V.B. Mattis, J.J. Breunig, C.N. Svendsen,  
43 40 Inducible Expression of GDNF in Transplanted iPSC-Derived Neural Progenitor Cells, *Stem*  
44 41 *Cell Reports* 10(6) (2018) 1696-1704.  
45 42 [40] A. Bakshi, S. Shimizu, C.A. Keck, S. Cho, D.G. LeBold, D. Morales, E. Arenas, E.Y.  
46 43 Snyder, D.J. Watson, T.K. McIntosh, Neural progenitor cells engineered to secrete GDNF show  
47 44 enhanced survival, neuronal differentiation and improve cognitive function following traumatic  
48 45 brain injury, *Eur J Neurosci* 23(8) (2006) 2119-34.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 1 [41] C. Deister, C.E. Schmidt, Optimizing neurotrophic factor combinations for neurite  
5 2 outgrowth, *J Neural Eng* 3(2) (2006) 172-9.  
6 3 [42] D. Santos, F. Gonzalez-Perez, X. Navarro, J. Del Valle, Dose-Dependent Differential Effect  
7 4 of Neurotrophic Factors on In Vitro and In Vivo Regeneration of Motor and Sensory Neurons,  
8 5 *Neural Plast* 2016 (2016) 4969523.  
9 6 [43] S. Takaku, H. Yanagisawa, K. Watabe, H. Horie, T. Kadoya, K. Sakumi, Y. Nakabeppu, F.  
10 7 Poirier, K. Sango, GDNF promotes neurite outgrowth and upregulates galectin-1 through the  
11 8 RET/PI3K signaling in cultured adult rat dorsal root ganglion neurons, *Neurochem Int* 62(3)  
12 9 (2013) 330-9.  
13 10 [44] W.A. Lackington, Z. Koci, T. Alekseeva, A.J. Hibbitts, S.L. Kneafsey, G. Chen, F.J.  
14 11 O'Brien, Controlling the dose-dependent, synergistic and temporal effects of NGF and GDNF by  
15 12 encapsulation in PLGA microparticles for use in nerve guidance conduits for the repair of large  
16 13 peripheral nerve defects, *J Control Release* 304 (2019) 51-64.  
17 14 [45] R. Pellitteri, A. Russo, S. Stanzani, D. Zaccheo, Olfactory ensheathing cells protect cortical  
18 15 neuron cultures exposed to hypoxia, *CNS Neurol Disord Drug Targets* 14(1) (2015) 68-76.  
19 16 [46] J. Nielsen, K. Gotfryd, S. Li, N. Kulahin, V. Soroka, K.K. Rasmussen, E. Bock, V. Berezin,  
20 17 Role of glial cell line-derived neurotrophic factor (GDNF)-neural cell adhesion molecule  
21 18 (NCAM) interactions in induction of neurite outgrowth and identification of a binding site for  
22 19 NCAM in the heel region of GDNF, *J Neurosci* 29(36) (2009) 11360-76.  
23 20 [47] C. Tohda, E. Joyashiki, Somnone enhances neurite outgrowth and spatial memory mediated  
24 21 by the neurotrophic factor receptor, RET, *Br J Pharmacol* 157(8) (2009) 1427-40.  
25 22 [48] W. Gu, F. Zhang, Q. Xue, Z. Ma, P. Lu, B. Yu, Bone mesenchymal stromal cells stimulate  
26 23 neurite outgrowth of spinal neurons by secreting neurotrophic factors, *Neurol Res* 34(2) (2012)  
27 24 172-80.  
28 25 [49] Z. Zhang, Y. Zhang, F. Gao, S. Han, K.S. Cheah, H.F. Tse, Q. Lian, CRISPR/Cas9  
29 26 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects, *Mol Ther*  
30 27 *Nucleic Acids* 9 (2017) 230-241.  
31 28 [50] J. Shao, M. Wang, G. Yu, S. Zhu, Y. Yu, B.C. Heng, J. Wu, H. Ye, Synthetic far-red light-  
32 29 mediated CRISPR-dCas9 device for inducing functional neuronal differentiation, *Proc Natl Acad*  
33 30 *Sci U S A* 115(29) (2018) E6722-E6730.  
34 31 [51] J.B. Black, A.F. Adler, H.G. Wang, A.M. D'Ippolito, H.A. Hutchinson, T.E. Reddy, G.S.  
35 32 Pitt, K.W. Leong, C.A. Gersbach, Targeted Epigenetic Remodeling of Endogenous Loci by  
36 33 CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells,  
37 34 *Cell Stem Cell* 19(3) (2016) 406-14.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

# 1 Graphical abstract



2

**Supplementary Information**

[Click here to download Supplementary Files: Revised Supplementary Information.DOCX](#)



Manuscript with changes tracked

[Click here to download Supplementary Files: Revised manuscript\\_changes marked.DOCX](#)

**Supplementary Information with changes tracked**

[Click here to download Supplementary Files: Revised Supplementary Information\\_changes marked.DOCX](#)

**Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: